Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Twin Capital Management Inc.

Twin Capital Management Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 4,001 shares of the biopharmaceutical company’s stock after selling 94 shares during the period. Twin Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,514,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Ronald Blue Trust Inc. increased its holdings in Regeneron Pharmaceuticals by 18.8% in the 3rd quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 12 shares during the last quarter. Drive Wealth Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 4.0% in the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 12 shares in the last quarter. Cassia Capital Partners LLC grew its stake in shares of Regeneron Pharmaceuticals by 2.3% in the third quarter. Cassia Capital Partners LLC now owns 589 shares of the biopharmaceutical company’s stock worth $485,000 after acquiring an additional 13 shares in the last quarter. Sutton Wealth Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares in the last quarter. Finally, Clearview Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 1.5% in the fourth quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after acquiring an additional 13 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now owns 1,382 shares in the company, valued at $1,325,338. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,729 shares of company stock worth $13,124,641. 8.83% of the stock is owned by company insiders.

Analysts Set New Price Targets

REGN has been the subject of several research reports. Bank of America boosted their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 12th. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. UBS Group boosted their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $976.41.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded down $3.53 on Thursday, reaching $897.66. 183,903 shares of the stock were exchanged, compared to its average volume of 491,315. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The business has a fifty day moving average price of $955.19 and a two-hundred day moving average price of $890.52. The firm has a market capitalization of $98.53 billion, a PE ratio of 25.93, a PEG ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the business posted $10.96 earnings per share. The business’s revenue was up .6% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.58 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.